A five-factor biomarker profile obtained week 4–12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2

Health Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2

(2015) Anne V. Soerensen et al.   EUROPEAN UROLOGY

Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative Stress

(2013) Stephanie Lankhorst et al.   ANTIOXIDANTS & REDOX SIGNALING

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2

(2013) Anne V. Soerensen et al.   EUROPEAN JOURNAL OF CANCER

The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium

(2013) Fabio A.B. Schutz et al.   EUROPEAN UROLOGY

Mild hyponatremia is associated with an increased risk of death in an ambulatory setting

(2013) Fabrice Gankam-Kengne et al.   KIDNEY INTERNATIONAL

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

(2013) Daniel YC Heng et al.   LANCET ONCOLOGY

Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy

(2012) Atsunari Kawashima et al.   INTERNATIONAL JOURNAL OF UROLOGY

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

(2012) Hai T Tran et al.   LANCET ONCOLOGY

Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

(2011) Petri Bono et al.   ACTA ONCOLOGICA

The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy

(2011) Robyn Macfarlane et al.   CANCER

Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group

(2011) Judith Manola et al.   CLINICAL CANCER RESEARCH

IL-6 plays an essential role in neutrophilia under inflammation

(2011) Misato Hashizume et al.   CYTOKINE

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

(2011) B. I. Rini et al.   JNCI-Journal of the National Cancer Institute

Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma

(2010) A N Jeppesen et al.   BRITISH JOURNAL OF CANCER

Hypothyroidism in patients with renal cell carcinoma

(2010) Manuela Schmidinger et al.   CANCER

Moving towards dose individualization of tyrosine kinase inhibitors

(2010) Heinz-Josef Klümpen et al.   CANCER TREATMENT REVIEWS

Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib

(2010) L. M. Riesenbeck et al.   WORLD JOURNAL OF UROLOGY

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

(2009) Daniel Y.C. Heng et al.   JOURNAL OF CLINICAL ONCOLOGY